Location Status of State Exchange Decision Medicaid Expansion Decision Executive Activity
United States 18 Declared State-based Exchange; 7 Planning for Partnership Exchange; 26 Default to Federal Exchange 29 Supports; 20 Opposes; 2 Weighing Options
Alabama Default to Federal Exchange Opposes
Alaska Default to Federal Exchange Opposes
Arizona Default to Federal Exchange Supports
Arkansas Planning for Partnership Exchange Supports1
California Declared State-based Exchange Supports
Colorado Declared State-based Exchange Supports1
Connecticut Declared State-based Exchange Supports
Delaware Planning for Partnership Exchange Supports
District of Columbia Declared State-based Exchange Supports
Florida Default to Federal Exchange Supports
Georgia Default to Federal Exchange Opposes
Hawaii Declared State-based Exchange Supports
Idaho Declared State-based Exchange Opposes2
Illinois Planning for Partnership Exchange Supports
Indiana Default to Federal Exchange Opposes2
Iowa Planning for Partnership Exchange Opposes
Kansas Default to Federal Exchange3 Weighing Options
Kentucky Declared State-based Exchange Supports
Louisiana Default to Federal Exchange Opposes
Maine Default to Federal Exchange3 Opposes
Maryland Declared State-based Exchange Supports1
Massachusetts Declared State-based Exchange Supports
Michigan Planning for Partnership Exchange Supports
Minnesota Declared State-based Exchange Supports1
Mississippi Default to Federal Exchange4 Opposes
Missouri Default to Federal Exchange Supports
Montana Default to Federal Exchange3 Supports
Nebraska Default to Federal Exchange3 Opposes
Nevada Declared State-based Exchange Supports
New Hampshire Planning for Partnership Exchange Supports
New Jersey Default to Federal Exchange Supports
New Mexico Declared State-based Exchange Supports1
New York Declared State-based Exchange Supports1
North Carolina Default to Federal Exchange Opposes5
North Dakota Default to Federal Exchange Supports1
Ohio Default to Federal Exchange3 Supports
Oklahoma Default to Federal Exchange Opposes
Oregon Declared State-based Exchange Supports
Pennsylvania Default to Federal Exchange Opposes2
Rhode Island Declared State-based Exchange Supports
South Carolina Default to Federal Exchange Opposes
South Dakota Default to Federal Exchange3 Weighing Options6
Tennessee Default to Federal Exchange Opposes7
Texas Default to Federal Exchange Opposes
Utah Default to Federal Exchange8 Opposes5
Vermont Declared State-based Exchange Supports
Virginia Default to Federal Exchange3 Opposes9
Washington Declared State-based Exchange Supports
West Virginia Planning for Partnership Exchange Supports
Wisconsin Default to Federal Exchange Opposes
Wyoming Default to Federal Exchange Opposes5
via Table Viewer.
Share this Policy Think Shop Resource:
Like this:
Like Loading...
Filed under: Blogosphere, Health Literacy, Health Policy, Healthcare Reform, health reform; health insurance reform; medical care; affordable healthcare; healthcare costs; health policy; healthcare politics;, State Health Exchanges
April 6, 2013 • 4:06 am 1
2010 > FDA Approves New Formulation for OxyContin
Oxycontin is still a drug abuse problem in our society… The FDA approved a new version of the drug back in 2010 and the company is supposed to do a followup study to tell us how safe the new FDA approved version is…. Have you seen the study? Five years have gone by and God knows how many addictions and lives?
“The reformulated OxyContin is intended to prevent the opioid medication from being cut, broken, chewed, crushed or dissolved to release more medication. The new formulation may be an improvement that may result in less risk of overdose due to tampering, and will likely result in less abuse by snorting or injection; but it still can be abused or misused by simply ingesting larger doses than are recommended.
“Although this new formulation of OxyContin may provide only an incremental advantage over the current version of the drug, it is still a step in the right direction,” said Bob Rappaport, M.D., director of the Division of Anesthesia and Analgesia Products in the FDA’s Center for Drug Evaluation and Research.
“As with all opioids, safety is an important consideration,” he said. “Prescribers and patients need to know that its tamper-resistant properties are limited and need to carefully weigh the benefits and risks of using this medication to treat pain.”
According to the U.S. Substance Abuse and Mental Health Services Administration’s National Survey on Drug Use and Health, approximately half a million people used OxyContin non-medically for the first time in 2008.
The manufacturer of OxyContin, Purdue Pharma L.P., will be required to conduct a postmarket study to collect data on the extent to which the new formulation reduces abuse and misuse of this opioid. The FDA is also requiring a REMS (Risk Evaluation and Mitigation Strategy) that will include the issuance of a Medication Guide to patients and a requirement for prescriber education regarding the appropriate use of opioid analgesics in the treatment of pain.”
See:
http://healththinkshop.com/2013/04/06/there-is-a-reason-why-we-have-a-war-on-drugs-and-why-we-cannot-win-it/
Aslo see more via 2010 > FDA Approves New Formulation for OxyContin.
Rate this:
Share this Policy Think Shop Resource:
Like this:
Filed under: Behavioral Health Outcomes, Blogosphere, Community Tragedy, consumers, Crimes and Misdemeanors, Death and Dying, Health Literacy, Health Policy, News, Parenting, Policy ThinkShop Comments on other media platforms, Political Economy, Public Health, Public Policy